European Market Overview: The European market is experiencing a positive trend, with the STOXX Europe 600 Index rising by 1.18% due to easing trade tensions and optimism regarding U.S. interest rate cuts.
Penny Stocks Potential: Investors are encouraged to explore penny stocks, which, despite their smaller size, can offer growth opportunities if they have strong financials and fundamentals.
Highlighted Companies: Notable penny stocks include Angler Gaming, Pharming Group, and Oriola Oyj, each with varying market caps and financial health ratings, showcasing different operational strengths and challenges.
Investment Caution: The article emphasizes that while the analysis provides insights into potential investments, it does not constitute financial advice and should be considered in light of individual investment goals and situations.
Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is 39.50 USD with a low forecast of 37.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is 39.50 USD with a low forecast of 37.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 19.930
Low
37.00
Averages
39.50
High
42.00
Current: 19.930
Low
37.00
Averages
39.50
High
42.00
Guggenheim
Debjit Chattopadhyay
Buy
maintain
$32 -> $39
2025-12-04
Reason
Guggenheim
Debjit Chattopadhyay
Price Target
$32 -> $39
AI Analysis
2025-12-04
maintain
Buy
Reason
Guggenheim analyst Debjit Chattopadhyay raised the firm's price target on Pharvaris to $39 from $32 and keeps a Buy rating on the shares after the company shared that its RAPIDe-3 trial hit on the primary and all 11 secondary endpoints. Post the RAPIDe-3 topline data readout, the firm is increasing its global peak sales estimate for deucrictibant to $1.65B from $1.4B during 2037.
Oppenheimer
Oppenheimer
Outperform
maintain
$41 -> $42
2025-11-07
Reason
Oppenheimer
Oppenheimer
Price Target
$41 -> $42
2025-11-07
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Pharming to $42 from $41 and keeps an Outperform rating on the shares. The firm notes the company reported strong Q3 results with $97M in sales, meaningfully above its estimates and generally in line with consensus of $90M/$98M, respectively.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PHAR
Unlock Now
Oppenheimer
Jeff Jones
Outperform
maintain
$40 -> $41
2025-08-01
Reason
Oppenheimer
Jeff Jones
Price Target
$40 -> $41
2025-08-01
maintain
Outperform
Reason
Oppenheimer analyst Jeff Jones raised the firm's price target on Pharming to $41 from $40 and keeps an Outperform rating on the shares after the company announced Q2 results. Moving into the second half of 2025, Oppenheimer anticipates competitive pressure on Ruconest from Ekterly, potentially up to a 20% hit by year-end 2026 as patients try the oral option, its estimates counterbalanced by reduced expenses.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$37
2025-03-21
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$37
2025-03-21
Reiterates
Strong Buy
Reason
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
